Suggested remit: To appraise the clinical and cost effectiveness of idecabtagene vicleucel within its marketing authorisation for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies.
Status In progress
Process STA 2018
ID number 1442

Provisional Schedule

Expected publication 25 August 2021

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
17 July 2020 - 14 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 June 2020 In progress. Topic is in progress
08 June 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma. This appraisal has been rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from NICE’s reporting targets for timeliness. In addition, as the delay will mean a NICE recommendation will not be available at the point of marketing authorisation, the company accepts that funding will only be available after the NICE recommendation, and not during the interim period between marketing authorisation and NICE recommendation. For information, this appraisal is now anticipated to begin during early October 2020 when we will write to you about how you can get involved.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance